Press Release Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock Jul 21
Press Release Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) Jul 20